Amgen expands trial of Cytokinetics heart failure drug
San Francisco Business Times (blog)
The goal of the trial is to study omecamtiv mecarbil's safety, tolerability and pharmacokinetics — or how the body reacts to the drug — in patients with heart failure and left ventricular systolic dysfunction. Patients in the 20-week trial over about ...
Cytokinetics Announces the Opening to Enrollment of the Expansion of COSMIC ...ACN Newswire (press release)

all 5 news articles »